Gilead Sciences

• U.S. gives full approval to 1st COVID-19 drug for young children

  The U.S. drug regulator on Monday granted the first full approval for treating COVID-19 in children aged 28 days and older to Gilead Sciences Inc's GILD.O drug remdesivir.

  Health

  Apr 25, 2022
  
• Gilead says counterfeit versions of its HIV drug were sold to patients over past 2 years

  The drugmaker said it found 85,247 bottles that had been tampered with or faked, including versions of its Biktarvy and Descovy treatments.

  Health

  Jan 19, 2022
  
• Advertisement
• FDA approves first coronavirus drug, may help recovery

  The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

  World

  Oct 22, 2020
• Advertisement
• Remdesivir cut coronavirus recovery time by 5 days, company’s final study suggests

  The antiviral drug, which was recently used to treat U.S. President Donald Trump, also appeared to reduce the risk of death in some patients.

  Health

  Oct 8, 2020
• U.S. buys up worldwide stock of remdesivir, drug seen as potential COVID-19 treatment

  The Department of Health and Human Services has secured more than 500,000 treatment courses of the drug from its sole manufacturer Gilead for American hospitals through September.

  Health

  Jun 30, 2020
• Coronavirus drug remdesivir to cost $2,340 per patient in the U.S.

  The amount that patients pay out of pocket depends on insurance, income and other factors.

  World

  Jun 29, 2020
• Coronavirus: Drug trial sees ‘encouraging’ results but researchers say more study needed

  Nearly 70 per cent of patients tested in the U.S., Europe, Canada and Japan improved after taking the Gilead Sciences drug remdesivir, but eight of the patients worsened while seven died.

  Health

  Apr 10, 2020